Skip to main content

Event Category


Article available in the folowing languages:

University College Dublin Looks forward to Welcoming the Innovative Medicines Initiative to Ireland

Dublin, Ireland, 11 October 2019, University College Dublin (UCD) will host an event with the Innovative Medicines Initiative (IMI) which is the world's biggest public-private partnership in the life sciences. IMI aims to facilitate collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

17 October 2019 - 17 October 2019
Dublin, Belgium

Organised by the UCD EU Research Office the seminar will explore IMI funding opportunities under Horizon 2020 and will provide perspectives on funding from current and past IMI applicants, an EU project management consultancy, an IMI Scientific Committee member as well as a patient representative body.

Dr Hugh Laverty, Head of Scientific Operations at IMI based in Brussels will provide an overview of IMI funding opportunities available under Horizon 2020. The event will also involve a panel of speakers giving perspectives on IMI funding including:
 Professor Dolores Cahill, UCD School of Medicine and Vice-Chair of the IMI Scientific Committee;
 Assistant Professor Fiona McGillicuddy, UCD School of Medicine and current IMI funding Stage 2 applicant;
 Ciaran Clissmann, Pintail Ltd, a consultant who supports IMI funding proposals and has recently been involved in a successful IMI proposal;
 A patient representative body.

In addition, the event will also have an address from Ciaran Duffy, National Contact Point, H2020 Health, and Member State Representative, IMI who will discuss 'the Future of IMI in Horizon Europe'.

Triona McCormack, Director of Research, UCD said, "We are delighted to welcome Dr Hugh Laverty of IMI to speak to the UCD community as well as the broader Irish health research community about IMI's funding opportunities. We very much value the unique objectives of IMI to bring research, industry and societal sectors together to make advances in efficient and effective medicines and treatments and for all stakeholders. IMI is a great example of how public private partnerships can advance healthcare and deliver solutions that will benefit our citizens. We are encouraged to see an increased focus on partnership programmes such as this in the future Horizon Europe programme across many sectors."